HEMATO

Seconds from raw cytometry to **sound decisions**

Today's cytometry workflows are slow, inconsistent, and rigid. Manual gating takes hours, varies between analysts, training takes years, and urgent cases are often delayed. Collaboration is cumbersome, relying on screenshots or sharing one screen. **Labs urgently need a way to maintain quality under rising caseloads and a shrinking workforce.**



hema.to is an AI-driven cytometry platform that takes you from raw data to report. It detects and classifies populations automatically, works across any cytometer, panel, or SOP, and delivers reproducible results every time. Analysts retain full transparency and control.

hema.to excels in efficiency. Urgent cases are flagged automatically, populations classified with AI, and reports generated directly in the browser—no VPNs or installs.

For legal and quality, each analysis is traceable and built for IVDR compliance. For IT and security, hema.to is privacy-first and GDPR-compliant: client-side anonymization, encrypted EU storage, role-based access, audit trails, and 2FA.

hema.to is uniquely SOP-, panel-, and device-agnostic while combining automatic transfer, analysis, reporting, and cloud access. No other platform brings all of this together.

To complete the final step toward the workflow of the future, we are running a 12-week early access program Free of charge. This includes configuration and validation of the AI to your panels and regular feedback sessions. Eight labs across Europe are already enrolled. This program is for **pioneer labs,** ready to innovate and shape the future of cytometry analysis.

hema.to is a Munich-based startup founded in 2021. Our 17-person team unites cytometry, AI, software, and regulatory expertise, backed by €7.7M in venture funding and advised by international leaders in hematology and diagnostics.

If you want to shape the next generation of cytometry workflows, Athina Chavli (athina@hema.to) can demo hema.to, or onboard you on our early access program.

hema.to GmbH
Munich, Germany
hema.to | linkedin.com/company/hemato

Proudly backed by LUMO Labs (🇳🇱); Elaia Partners (🇫🇷)
Heal Capital, HTGF, Bayern Kapital (🇩🇪)
& Labor Becker (🇩🇪)